Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the Ovarian Cancer Association Consortium pooled analysis.

Pearce CL, Wu AH, Gayther SA, Bale AE; Australian Cancer Study (Ovarian Cancer) and Australian Cancer Study Group, Beck PA, Beesley J, Chanock S, Cramer DW, DiCioccio R, Edwards R, Fredericksen ZS, Garcia-Closas M, Goode EL, Green AC, Hartmann LC, Hogdall E, Kjaer SK, Lissowska J, McGuire V, Modugno F, Moysich K, Ness RB, Ramus SJ, Risch HA, Sellers TA, Song H, Stram DO, Terry KL, Webb PM, Whiteman DC, Whittemore AS, Zheng W, Pharoah PD, Chenevix-Trench G, Pike MC, Schildkraut J, Berchuck A; Ovarian Cancer Association Consortium.

Br J Cancer. 2008 Jan 29;98(2):282-8. doi: 10.1038/sj.bjc.6604170. Epub 2008 Jan 22.

2.

Clarifying the PROGINS allele association in ovarian and breast cancer risk: a haplotype-based analysis.

Pearce CL, Hirschhorn JN, Wu AH, Burtt NP, Stram DO, Young S, Kolonel LN, Henderson BE, Altshuler D, Pike MC.

J Natl Cancer Inst. 2005 Jan 5;97(1):51-9.

PMID:
15632380
3.

Genetic variation in the progesterone receptor gene and risk of endometrial cancer: a haplotype-based approach.

Lee E, Hsu C, Haiman CA, Razavi P, Horn-Ross PL, Van Den Berg D, Bernstein L, Le Marchand L, Henderson BE, Setiawan VW, Ursin G.

Carcinogenesis. 2010 Aug;31(8):1392-9. doi: 10.1093/carcin/bgq113. Epub 2010 Jun 13.

4.

Progesterone receptor PROGINS and +331G/A polymorphisms confer susceptibility to ovarian cancer: a meta-analysis based on 17 studies.

Liu T, Chen L, Sun X, Wang Y, Li S, Yin X, Wang X, Ding C, Li H, Di W.

Tumour Biol. 2014 Mar;35(3):2427-36. doi: 10.1007/s13277-013-1322-x. Epub 2013 Nov 7.

PMID:
24197980
5.

Progesterone receptor (PROGINS) polymorphism and the risk of ovarian cancer.

Leite DB, Junqueira MG, de Carvalho CV, Massad-Costa AM, Gonçalves WJ, Nicolau SM, Lopes LA, Baracat EC, da Silva ID.

Steroids. 2008 Jul;73(6):676-80. doi: 10.1016/j.steroids.2008.02.005. Epub 2008 Feb 23.

PMID:
18384825
6.

Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers.

Berchuck A, Schildkraut JM, Wenham RM, Calingaert B, Ali S, Henriott A, Halabi S, Rodriguez GC, Gertig D, Purdie DM, Kelemen L, Spurdle AB, Marks J, Chenevix-Trench G.

Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2141-7.

7.

Polymorphisms of MUC16 (CA125) and MUC1 (CA15.3) in relation to ovarian cancer risk and survival.

Williams KA, Terry KL, Tworoger SS, Vitonis AF, Titus LJ, Cramer DW.

PLoS One. 2014 Feb 13;9(2):e88334. doi: 10.1371/journal.pone.0088334. eCollection 2014.

8.

Progesterone receptor polymorphisms and risk of breast cancer: results from two Australian breast cancer studies.

Johnatty SE, Spurdle AB, Beesley J, Chen X, Hopper JL, Duffy DL, Chenevix-Trench G; Kathleen Cuningham Consortium for Research in Familial Breast Cancer.

Breast Cancer Res Treat. 2008 May;109(1):91-9. Epub 2007 Jun 26.

PMID:
17592773
9.

Progesterone receptor gene variants and risk of endometrial cancer.

O'Mara TA, Fahey P, Ferguson K, Marquart L, Lambrechts D, Despierre E, Vergote I, Amant F, Hall P, Liu J, Czene K; SASBAC, Rebbeck TR; WISE Study Group; AOCS Management Group; SEARCH, Ahmed S, Dunning AM, Gregory CS, Shah M; ANECS, Webb PM, Spurdle AB.

Carcinogenesis. 2011 Mar;32(3):331-5. doi: 10.1093/carcin/bgq263. Epub 2010 Dec 10.

10.

Analyze association of the progesterone receptor gene polymorphism PROGINS with ovarian cancer risk.

Yuan C, Wang C, Liu X, Kong B.

Mol Biol Rep. 2013 Oct;40(10):6001-10. doi: 10.1007/s11033-013-2709-x. Epub 2013 Sep 21.

PMID:
24057181
11.

Analysis of the human progesterone receptor gene polymorphism progins in Austrian ovarian carcinoma patients.

Tong D, Fabjani G, Heinze G, Obermair A, Leodolter S, Zeillinger R.

Int J Cancer. 2001 Nov 20;95(6):394-7.

12.

ESR1/SYNE1 polymorphism and invasive epithelial ovarian cancer risk: an Ovarian Cancer Association Consortium study.

Doherty JA, Rossing MA, Cushing-Haugen KL, Chen C, Van Den Berg DJ, Wu AH, Pike MC, Ness RB, Moysich K, Chenevix-Trench G, Beesley J, Webb PM, Chang-Claude J, Wang-Gohrke S, Goodman MT, Lurie G, Thompson PJ, Carney ME, Hogdall E, Kjaer SK, Hogdall C, Goode EL, Cunningham JM, Fridley BL, Vierkant RA, Berchuck A, Moorman PG, Schildkraut JM, Palmieri RT, Cramer DW, Terry KL, Yang HP, Garcia-Closas M, Chanock S, Lissowska J, Song H, Pharoah PD, Shah M, Perkins B, McGuire V, Whittemore AS, Di Cioccio RA, Gentry-Maharaj A, Menon U, Gayther SA, Ramus SJ, Ziogas A, Brewster W, Anton-Culver H; Australian Ovarian Cancer Study Management Group; Australian Cancer Study (Ovarian Cancer), Pearce CL; Ovarian Cancer Association Consortium (OCAC).

Cancer Epidemiol Biomarkers Prev. 2010 Jan;19(1):245-50. doi: 10.1158/1055-9965.EPI-09-0729.

13.

Progesterone receptor gene polymorphisms and risk of endometriosis: results from an international collaborative effort.

Near AM, Wu AH, Templeman C, Van Den Berg DJ, Doherty JA, Rossing MA, Goode EL, Cunningham JM, Vierkant RA, Fridley BL, Chenevix-Trench G, Webb PM, Kjær SK, Hogdall E, Gayther SA, Ramus SJ, Menon U, Gentry-Maharaj A, Schildkraut JM, Moorman PG, Palmieri RT, Ness RB, Moysich K, Cramer DW, Terry KL, Vitonis AF, Pike MC, Berchuck A, Pearce CL; Ovarian Cancer Association Consortium; Australian Cancer Study (Ovarian Cancer) (ACS); Australian Ovarian Cancer Study Group (AOCS).

Fertil Steril. 2011 Jan;95(1):40-5. doi: 10.1016/j.fertnstert.2010.06.059. Epub 2010 Aug 17.

14.

Association of progesterone receptor gene (PGR) variants and breast cancer risk in African American women.

Gabriel CA, Mitra N, Demichele A, Rebbeck T.

Breast Cancer Res Treat. 2013 Jun;139(3):833-43. doi: 10.1007/s10549-013-2592-0. Epub 2013 Jun 14.

15.

Two functionally relevant polymorphisms in the human progesterone receptor gene (+331 G/A and progins) and the predisposition for breast and/or ovarian cancer.

Romano A, Lindsey PJ, Fischer DC, Delvoux B, Paulussen AD, Janssen RG, Kieback DG.

Gynecol Oncol. 2006 May;101(2):287-95. Epub 2005 Dec 19.

PMID:
16360811
16.

Polymorphisms at the glutathione S-transferase GSTM1, GSTT1 and GSTP1 loci: risk of ovarian cancer by histological subtype.

Spurdle AB, Webb PM, Purdie DM, Chen X, Green A, Chenevix-Trench G.

Carcinogenesis. 2001 Jan;22(1):67-72.

PMID:
11159743
17.

PGR +331 A/G and increased risk of epithelial ovarian cancer.

Risch HA, Bale AE, Beck PA, Zheng W.

Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1738-41.

18.

Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives.

Runnebaum IB, Wang-Gohrke S, Vesprini D, Kreienberg R, Lynch H, Moslehi R, Ghadirian P, Weber B, Godwin AK, Risch H, Garber J, Lerman C, Olopade OI, Foulkes WD, Karlan B, Warner E, Rosen B, Rebbeck T, Tonin P, Dubé MP, Kieback DG, Narod SA.

Pharmacogenetics. 2001 Oct;11(7):635-8.

PMID:
11668223
19.

Association study of prostate cancer susceptibility variants with risks of invasive ovarian, breast, and colorectal cancer.

Song H, Koessler T, Ahmed S, Ramus SJ, Kjaer SK, Dicioccio RA, Wozniak E, Hogdall E, Whittemore AS, McGuire V, Ponder BA, Turnbull C, Hines S, Rahman N; Breast Cancer Susceptibility Collaboration UK, Eeles RA, Easton DF, Gayther SA, Dunning AM, Pharoah PD.

Cancer Res. 2008 Nov 1;68(21):8837-42. doi: 10.1158/0008-5472.CAN-08-2363.

20.

Vitamin D receptor rs2228570 polymorphism and invasive ovarian carcinoma risk: pooled analysis in five studies within the Ovarian Cancer Association Consortium.

Lurie G, Wilkens LR, Thompson PJ, Carney ME, Palmieri RT, Pharoah PD, Song H, Hogdall E, Kjaer SK, DiCioccio RA, McGuire V, Whittemore AS, Gayther SA, Gentry-Maharaj A, Menon U, Ramus SJ, Goodman MT; Ovarian Cancer Association Consortium.

Int J Cancer. 2011 Feb 15;128(4):936-43. doi: 10.1002/ijc.25403.

Supplemental Content

Support Center